Program
AMG 732
A development code.
Its studies are mostly in Graves Ophthalmopathy, led by Amgen.
Furthest: phase 2, since May 2, 20242 company-led studies, 2 open or runningNext primary completion: Jan 6, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgen | 22 open or running | phase 2since May 2, 2024 | May 2, 2024 | Jan 6, 2027phase 2 · NCT06401044 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 2, 2024First study: phase 2 study in Graves OphthalmopathyFirst studyNCT06401044 · 94 enrolled · United States, Australia, Canada and more
- Feb 23, 2026Phase 2 study in Graves OphthalmopathyNCT07438405 · 30 planned · United States, Poland, Spain and more
Ahead
- Jan 6, 2027Primary completion: phase 2 study in Graves OphthalmopathyNCT06401044
- Jan 29, 2028Primary completion: phase 2 study in Graves OphthalmopathyNCT07438405
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07438405Graves Ophthalmopathy · United States, Poland, Spain and more | 2 | Recruiting | Jan 29, 2028 | 30 |
| NCT06401044Graves Ophthalmopathy · United States, Australia, Canada and more | 2 | Active, not recruiting | Jan 6, 2027 | 94 |
How it is read
Names in the registry
- “AMG 732”, 2 entries
Codes read as this program: AMG732.
Conditions, from the studies’ own filings
- Graves Ophthalmopathy, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.